Press Releases

March 01, 2021
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus Encequidar Klisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021 The New England Journal of Medicine published Phase III trial data on the efficacy and safety of Klisyri® Product sales
Printer Friendly Version 
March 01, 2021
Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer
Conference call and webcast scheduled for today at 8:00 a.m. ET BUFFALO, N.Y. , March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and
Printer Friendly Version 
February 22, 2021
Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021
BUFFALO, N.Y. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a
Printer Friendly Version 
February 18, 2021
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea . PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan , Singapore , and Malaysia Athenex’s
Printer Friendly Version 
February 11, 2021
Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)
The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, developed by Athenex , received FDA
Printer Friendly Version 
January 25, 2021
CEO Dr. Johnson Lau Recuperating from COVID at Home
BUFFALO, N.Y. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board Chairman,
Printer Friendly Version 
January 08, 2021
CEO Dr. Johnson Lau Contracts COVID-19
BUFFALO, N.Y. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that its CEO and Board Chairman, Dr.
Printer Friendly Version 
January 05, 2021
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
BUFFALO, N.Y. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. , (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that it will participate in the 39 th
Printer Friendly Version